NCT04067336 2025-11-10First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1/2 Recruiting263 enrolled 1 FDA
NCT02074839 2025-06-08Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationServierPhase 1 Recruiting291 enrolled 3 FDA